Surgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London

Similar documents
Liver resection for HCC

Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging

Management of HepatoCellular Carcinoma

EASL-EORTC Guidelines

Surgical resection for hepatocellular carcinoma (HCC)

Hepatocellular Carcinoma. Markus Heim Basel

TREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD

Surgery for hilar cholangiocirconoma

Unmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim

CHIRURGIA EPATOBILIARE IN WEEK SURGERY?

Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan

Liver transplantation: Hepatocellular carcinoma

Proximal Bile Duct Cancer: Contemporary Management. William R. Jarnagin, MD, FACS

9th Paris Hepatitis Conference

Radiation Therapy for Liver Malignancies

HEPATECTOMY. Surgical Potpourri Session. ACS NSQIP National Conference Salt Lake City 2012

Hepatocellular Carcinoma: Diagnosis and Management

Staging and prognostic systems: beyond BCLC?

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Treatment of Colorectal Liver Metastases State of the Art

Carcinoma del colon-retto: La Chirurgia Robotica nella Malattia Avanzata

Advances in percutaneous ablation for hepatocellular carcinoma

MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC

Reconsidering Liver Transplantation for HCC in a Era of Organ shortage

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC

Laparoscopic liver resections in surgical treatment of HCC

Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers

Surveillance for Hepatocellular Carcinoma

Management of Stage IV Colorectal Cancer: Expanding the Horizon

Pioneers in Laparoscopic HBP Surgery

Assessment of Liver Function: Implications for HCC Treatment

Trattamento chirurgico delle lesioni epatiche secondarie difficili. Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica

pitfall Table 1 4 disorientation pitfall pitfall Table 1 Tel:

Adult-to-adult living donor liver transplantation Triumphs and challenges

간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung

WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?

Professor Norbert Bräu

Tumor incidence varies significantly, depending on geographical location.

Hepatic resection is a well-accepted therapy for hepatocellular

Evolution of Surgery: Role of the Surgeon in the Molecular and Technology Age. Yuman Fong, MD Memorial Sloan-Kettering Cancer Center Rio 2010

The Management of Advanced Stage Hepatocellular Carcinoma

Colorectal Liver Metastases Metachronous

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice

Pediatric Liver Tumors and Transplantation. Northwest Regional Pediatric Live Disease Symposium, Seattle WA, April 12, 2008

HCC: Is it an oncological disease? - No

Liver surgery, acute GI tract bleeding

Staging & Current treatment of HCC

Treatment of HCC in real life-chinese perspective

Dr Adam Bartlett. General Surgeon Senior Lecturer University of Auckland Auckland City Hospital

RESEARCH ARTICLE. Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy

Live Donor Liver Transplantation: A Life Saving Option for End Stage Liver Disease

Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS

Laparoscopic Liver Resection for Hepatocellular Carcinoma

SEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA

UPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA*

Management of Rare Liver Tumours

Resection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy

Hepatocellular Carcinoma: Transplantation, Resection or Ablation?

SIRTEX Lunch Symposium, Cebu, 23 Nov Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong

6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration

Paul Martin MD FACG. University of Miami

Embolotherapy for Cholangiocarcinoma: 2016 Update

HIV and Hepatocellular Carcinoma. Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Rome May 2013

NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION

Laparoscopic vs Robotic Rectal Cancer Surgery: Making it better!

Management of Colorectal Liver Metastases

Liver Transplantation

Life After SVR for Cirrhotic HCV

Liver surgery for colorectal liver metastases. Keith Roberts, Consultant Liver Transplant and Liver/Pancreas Surgeon University Hospitals Birmingham

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

Long R. Jiao, David N. Hakim, Tamara M. H. Gall, Ana Fajardo, Tim D. Pencavel, Ruifang Fan, Mikael H. Sodergren

Hepatocellular carcinoma: Intra-arterial treatments

Margin status in liver resections for colorectal metastases Orlando Jorge M. Torres MD, PhD

Bariatric Surgery For Patients With End-Organ Failure

ITALIAN SURGICAL SOCIETY ENDOCRINE SURGERY SCHOOL LIVER METASTASIS FROM NEUROENDOCRINE TUMORS

Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center

Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines

Liver Transplantation Evaluation: Objectives

TACE: coming of age?

Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases

Jose Ramos. Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma

Index. Note: Page numbers of article titles are in boldface type.

Learning Objectives. After attending this presentation, participants will be able to:

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD

6 th August 2018 Day 1 - Gallbladder & Bile duct Topic

SIRT for Intermediate and Advanced HCC

Original article: new surgical approaches to the Klatskin tumour

Study Objective and Design

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

How to deal with synchronous primary and liver metastases

Therapeutic Response Assessment and Endpoints in HCC

Update in abdominal Surgery in cirrhotic patients

Update EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma

MANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011

Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010

Saudi Gastroenterology Association Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Summary of Recommendations

Hepatocellular Carcinoma (HCC): Burden of Disease

Techniques to Improve Resectability of Colorectal Liver Metastases Ching-Wei D. Tzeng, M.D.

Transcription:

Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London

Global distribution of HCC and staging systems WEST 1. Italy (Milan, CLiP) 2. France 3. Spain (Barcelona) EAST 1. Japan (JIS) 2. China (CUPI) 3. Korea (Hangzhou)

The arsenal of treatments for HCC Liver transplantation 15% Sorafenib Ablative treatments (TACE, PEI, etc) Best supportive care Resection 15%

Comparison of OS and DFS among available treatment options Gastroenterol Hepatol (N Y). 2014 Mar;10(3):153-61.

Determinants of surgical management Size of tumour Future liver remnant Liver function

Surgical management of HCC 20% HCC 80% No cirrhosis cirrhosis Resection Transplantation Bridging therapies Resection Transplantation Bridging therapies TACE RFA Alcohol injection Other

Non cirrhotic HCC The treatment of choice for non cirrhotic HCC is resection Visc Med. 2016 Apr;32(2):116-20. Perioperative mortality (0 6%) and morbidity (8 40%) of these patients are rather low Five-year and median overall survival rates after resection of noncirrhotic conventional HCC are 67 % and 137 months (95 % confidence interval [CI], 89 184 months) 5-year and median recurrence-free survival rates are 55 % and 108 months J Gastrointest Surg. 2016 Oct;20(10):1725-31 Dig Liver Dis. 2010 May;42(5):341-7.

Contraindications to resection among non cirrhotic HCC The contraindications to resection include: 1. All the contraindications for a hepatectomy 2. NASH related HCC: associated with impaired functional reserve and extent of resection should be considered with caution BMC Cancer. 2015 Apr 1;15:210. 3. Size of HCC is not a contraindication for resection, but affects outcomes as a prognostic factor Int J Surg. 2013;11(10):1078-82. J SurgOncol. 2017 Feb 13.

Liver transplantation in Non cirrhotic HCC Non resectable HCC and absence of macro vascular invasion absence of extra hepatic spread Or patients with previously resected HCC in a non-cirrhotic liver and have intrahepatic recurrence of HCC >12 m after no evidence of macro vascular invasion or extra hepatic spread Salvage transplantation Indian J Surg 2012 74(1):100-117

Cirrhosis BCLC 0 A Milan criteria Resection Within Without Transplantion Bridging therapies Re-assess

BCLC

Ideal for resection patient Has a solitary HCC confined to the liver No radiographic evidence of invasion of the hepatic vasculature No evidence of portal hypertension Well-preserved hepatic function.

Stage 0 and A with PH Established treatment LT or RFA However Long waiting time Drop out Limited availability of Donors High costs Surgery with better OS than RFA in single early HCC > 2cm In single very early HCC < 2cm LR gives similar OS with RFA J Gastrointest Surg 2011; 15: 311-320 Hepatol Res 2013; 43: 853-864 Alternatively LR and RFA J Hepatol 2012; 56: 412-418

BCLC A-B multiple HCCs not suitable for LT Established treatment RFA or TACE However Liver resection can give better long term results than TACE alone Ann Surg 2002; 235: 373-382 Ann Surg 2010; 252: 903-912 J Gastrointest Surg 2012

BCLC B Large HCC > 5cm Established treatment TACE However Surgery is as safe as TACE with better OS in many series NS survival benefit between preoperative TACE + surgery in comparison with surgery alone Ann Surg 2013; 257: 929-937 J Gastrointest Surg 2009; 13: 1313-1320

BCLC HCC stage C with Macrovasuclar invasion selected patients with PVTT may benefit from more aggressive treatment modalities World J Gastroenterol 2016 August 28; 22(32): 7289-7300 PV resection vs. Thrombectomy showed non significant difference regarding morbidity and mortality Same regarding long term results such OS and DFS Survival outcomes were far more better than no treatment or TACE World J Gastroenterol. 2015 Oct 21;21(39):11185-98

Anatomical vs Non anatomical Br J Surg. 2015 Jun;102(7):776-84

Anatomical vs Non anatomical Pros for anatomical Reduce risk of local/intrahepatic recurrence Cons of anatomical Technically challenging (lap?) Time consuming Alteration of hilar structures affecting subsequent transplantation Pros for non anatomical Parenchyma sparing Feasible laparoscopically Cons of non anatomical Blood loss Increased risk of local/intrahepatic recurrence Meta analysis with conflicting results based on observational studies Need for large randomized trials Ann Surg Oncol 2012;19:3697-3705

Anatomical vs Non anatomical HCV AFP Billirubin Tumor size 2-5 Surg Today. 2017 Feb;47(2):193-201.

Prognostic factors of outcomes HPB (Oxford). 2012 May;14(5):285-90

Recurrence post resection J Gastrointest Surg. 2016 Oct;20(10):1725-31

Re-resection for HCC Clear survival benefit

ALPPS and HCC Two stage hepatectomy Morbidity after second surgery 20%-60% Drop out rate 8%-31% 5year OS is reported to be 51% HPB. 2013; 15:483-491 ALPPS reported Morbidity( bile leakage and sepsis) 16-64% Mortality (Hepatic insufficiency) 12-23% Long term ongological outcomes are not yet available

ALPPS and HCC Open ALPPS for HCC in cirrhotic liver has been described in few case reports Laparoscopic ALLPS feasible by experts Robotic ALPPS may have place in HCC Large scale studies needed to further evaluate

Laparoscopic segments

Laparoscopic Approach for HCC Louisville USA 2008 Morioka Japan 2014 Solitary lesions less than 5cm Located in segments (II, III, IVb, V and VI) Away from hepatic hilum and IVC Non-compensated cirrhosis absolute contraindication Size limit over passed however lesions >10 cm relative contraindication Location over passed PVTT safe and feasible in selected patients by highly experts surgeons PH contraindication for resection > 3 segments

Laparoscopic Approach for HCC Advantages / Disadvantages Decrease rate of bleeding / need for transfusion Minimize post operative ascites Reduce adhesion formation Decrease LOS Decrease morbidity Issue with reproducibility Learning curve > 60 Requiring expertise in both liver surgery and advanced laparoscopy Available in HPB tertiary centers No differences regarding surgical margins and Long term results (OS and DFS) Ann Surg Oncol. 2013; 20:1203-1215

Robotic approach for HCC All liver segments surgery Complex hilar dissection Bilioenteric reconstruction

Robotic vs. laparoscopic approach Largest matched comparison from Pittsburgh No difference regarding mortality morbidity LOS and negative margin rate Operative time significantly longer for RLR irrespective type of hepatectomy (minor or major) However lack of prospective comparative studies in HCC field Ann Surg. 2014; 259:549-555

Innovative surgical approach for HCC 3-D surgical planning software 1. Simulating surgery 2. Calculating liver volumes PVE and stem cell application CD133+ bone marrow derived stem cells (role in the process of tissue regeneration) Need for further studies to ensure safety and effectiveness W J SurgOncol2013, 11:192 Ann Surg 2012, 255:79 85

Innovative surgical approach for HCC Robotic augmented reality (AR)- assisted liver resection Fusion between live images and synthetic computergenerated patient specific images is defined as augmented reality (AR) Langenbecks Arch Surg. 2015 Apr;400(3):381-5.

Suitable for LT patient with liver disease (usually cirrhosis) who would not tolerate liver resection who have a solitary HCC 5 cm in diameter or up to three separate lesions none of which is larger than 3 cm (within Milan criteria) no evidence of gross vascular invasion no regional nodal or distant metastases.

Events in the evolution of LTx for HCC

Transplantation criteria for HCC <1990 1993 1996 2001 2002 1. Pre 1990 s: all HCC transplanted 2. PB: Resectable better off transplantable 3. Milan criteria 4. UCSF: extended criteria 5. BCLC Disappointing results Improvement of LTx results

Transplantation for HCC

Transplantation for HCC BCLC 5yr OS MIlan down

Does the type of donor graft matter?

BCLC

BCLC Evolution Oncotarget. 2017 Jan 15. doi: 10.18632

Is LT effective among patients presented outside the Milan Criteria? J Am Coll Surg. 2017 Jan 6. pii: S1072-7515(16)31724-0

LTx vs LR: complimentary or different paths?

Outcomes of salvage LT in HCC In favour of Salvage World J Gastroenterol. 2012 May 21;18(19):2415-22.

HCC resection combined with LTx Resection of HCC follow up if recurrence Salvage Transplantation (ST) Resection as bridge to Transplantation List the patient for Tx Resection to keep him within Tx criteria Followed by Tx Resection as selection tool for Transplantation Resection-List the patient and do a preemptive Tx Resection as Down staging tool for Transplantation As outside criteria resection then follow up and Tx

World J Gastroenterol 2015 October 21; 21(39): 11185-11198

Recurrence after LT: the end of the line? Clear survival benefit

King s HCC management HCC referral (new patients) OP- review Cirrhosis P/S Cause of HCC Staging Patients on pathway of treatment Hepatologist Radiologist Surgeon Oncologist CNS Palliative care HCC MDM Decision to treat

Outcomes of multimodal management The longterm benefit of resection

Take home message HCC without cirrhosis: resection is the gold standard unless otherwise contraindicated HCC with cirrhosis: Early cirrhosis (C-P:A), solitary nodule: resection Early cirrhosis within Milan criteria (CP:A-B): LTx Early cirrhosis without Milan criteria (CP:A-B): Bridging therapies Significant cirrhosis (C-P:B-C) or out of Milan criteria: down staging/bridging therapies and re-assess Severe cirrhosis: Symptomatic treatment irrespective of the tumour Dynamic evolution of indications for LR and LT HCC is a disease best served by HPB centers where a MDM approach can take place